ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2012
In with the new: the determinants of prescribing innovation by general practitioners in Ireland.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review.BMC health services research · 2021Pooled it
- Factors affecting the uptake of new medicines: a systematic literature review.BMC health services research · 2014Pooled it
- Differential diffusion of pharmaceutical innovations in a mixed market middle - income economy.BMC health services research · 2021Article
- Regional Variance of the Early Use of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease.Kidney360 · 2020Article
- What are the current 'top five' perceived educational needs of Irish general practitioners?Irish journal of medical science · 2020Article
- Article
- Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending.BMC health services research · 2019Article
- Prescribing and practice development decision-making in Irish general practices.Irish journal of medical science · 2015Review
- Premium inflation in the Irish private health insurance market: drivers and consequences.Irish journal of medical science · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An important element of the process by which new drugs achieve widespread use is their adoption by GPs. In this paper, we explore the factors that shape the timing of the first prescription of six new drugs by General Practitioners in Ireland. Our analysis is based on a dataset that matches prescription data with data on GP characteristics. We then use duration analysis to explore both equilibrium and non-equilibrium determinants of prescribing innovation. Our study highlights a range of commonalities across all of the drugs considered and suggests the importance of GP and practice characteristics in shaping prescribing decisions. We also find strongly significant, and consistently signed, stock and order effects across these drugs: GPs who have a track record of early adoption tend also to be early adopters of other new drugs; and, the larger the proportion of GPs which have already adopted a new drug the slower is subsequent adoption. Epidemic and learning effects are also evident with slower adoption by rural practices and among those GPs with narrower prescribing portfolios.
Indexed as
Identifiers
21503785What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.